Protease Inhibitor Use During Pregnancy and Preterm Delivery
Researchers in Africa found that women on protease inhibitor-based HAART had higher rates of preterm delivery than those women on a NRTI regimen. These infants, however, were not more likely to have longer hospitalizations or higher rates of mortality. Researchers believe that PI use results in less weight gain in the third trimester, a risk factor for preterm delivery, and recommend further research.
Citation:
Powis KM, Kitch D, Ogwu A, Hughes MD, Lockman S, Leidner J, van Widenfelt E, Moffat C, Moyo S, Makhema J, Essex M, Shapiro RL. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 2011 Aug 15; 204:506-514.
Original Article (subscription may be required)
Abstract
Editorial Response:
Kourtis A, Fowler MG. Antiretroviral use during pregnancy and risk of preterm delivery: More questions than answers. J Infect Dis 2011 Aug 15; 204:493-494.
Original Article (subscription may be required)
Citation:
Powis KM, Kitch D, Ogwu A, Hughes MD, Lockman S, Leidner J, van Widenfelt E, Moffat C, Moyo S, Makhema J, Essex M, Shapiro RL. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 2011 Aug 15; 204:506-514.
Original Article (subscription may be required)
Abstract
Editorial Response:
Kourtis A, Fowler MG. Antiretroviral use during pregnancy and risk of preterm delivery: More questions than answers. J Infect Dis 2011 Aug 15; 204:493-494.
Original Article (subscription may be required)
